Efficacy of Cabazitaxel Treatment in Metastatic Castration Resistant Prostate Cancer in Second and Later Lines. An Experience from Two German Centers
| Autor: | Stefan Fuxius, Cathleen Spath, Sascha Pahernik, Sonia Vallet, Dirk Jäger, Carsten Grüllich, Stefanie Zschäbitz, Markus Hohenfellner, Stefan Duensing, Boris Hadaschik, Daniel Debatin, Andreas Karcher |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Oncology
medicine.medical_specialty 030232 urology & nephrology survival 03 medical and health sciences chemistry.chemical_compound Prostate cancer 0302 clinical medicine Castration Resistance castration resistance Internal medicine medicine Enzalutamide Progression-free survival sequencing therapy Lymph node Cabazitaxel business.industry Abiraterone acetate food and beverages prostate cancer medicine.disease medicine.anatomical_structure chemistry 030220 oncology & carcinogenesis Cohort business Research Paper medicine.drug |
| Zdroj: | Journal of Cancer |
| ISSN: | 1837-9664 |
| DOI: | 10.7150/jca.17644 |
| Popis: | Purpose: Several new treatment options for patients with metastatic castration resistant prostate cancer (mCRPC) have been approved within the last years - among them cabazitaxel (CAB), abiraterone acetate, enzalutamide, and radium-223. The aim of this study was to assess factors predictive for efficacy of CAB. Methods: We analyzed all patients with mCRPC treated with CAB at our institutions between 2011 and 2016. Data were retrieved retrospectively from the electronical patient chart. Results: 69 patients received CAB (26.1% 2nd line, 36.2% 3rd line, 37.3% >3rd line). Median overall survival (OS) on CAB was 10.0 months (95%CI 7.1-12.9). Median progression free survival (PFS) on CAB was 3.9 months (95%CI 3.0-4.8). There were no differences in OS and PFS regarding treatment line of CAB (2nd vs. higher; 2nd/3rd vs. higher). Duration of remission on 1st line treatment (> 6 months vs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|